Olson, K. E., Namminga, K. L., Lu, Y., Schwab, A. D., Thurston, M. J., Abdelmoaty, M. M., . . . Gendelman, H. E. (2021). Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. EBioMedicine.
Chicago ZitierstilOlson, Katherine E., et al. "Safety, Tolerability, and Immune-biomarker Profiling for Year-long Sargramostim Treatment of Parkinson's Disease." EBioMedicine 2021.
MLA ZitierstilOlson, Katherine E., et al. "Safety, Tolerability, and Immune-biomarker Profiling for Year-long Sargramostim Treatment of Parkinson's Disease." EBioMedicine 2021.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.